Henry Schein vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (85 vs 77)
Henry Schein logo

Henry Schein

LeaderHealthcare Tech

Enterprise

World's largest dental/medical distributor; recovered from 2023 ALPHV ransomware attack; $12.4B 2024 revenue; digital dentistry platform driving recurring tech revenue.

AI VisibilityBeta
Overall Score
B77
Category Rank
#47 of 290
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
74
Gemini
78

About

Henry Schein is the world's largest provider of health care solutions to office-based dental and medical practitioners, founded in 1932 by Henry Schein in Queens, New York, and headquartered in Melville, New York. The company trades on Nasdaq (HSIC) and generated approximately $12.4 billion in net sales in 2024, serving over one million healthcare practitioners across more than 30 countries. Henry Schein operates through two segments: Health Care Distribution, supplying dental and medical consumables, equipment, and technology; and Technology and Value-Added Services, offering practice management software and digital dentistry solutions under brands like Dentrix, Dexis, and Axium.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A85
Category Rank
#23 of 290
AI Consensus
78%
Trend
up
Per Platform
ChatGPT
91
Perplexity
90
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

77
Overall Score
85
#47
Category Rank
#23
80
AI Consensus
78
stable
Trend
up
72
ChatGPT
91
74
Perplexity
90
78
Gemini
89
75
Claude
94
80
Grok
84

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.